Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUNIMUD - Sunphenon EGCG in Duchenne Muscular Dystrophy
2009-016482-28Phase 2Terminated
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Mar 2010
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Duchenne muscular dystrophy (DMD) comparing Sunphenon EGCG with Placebo (2 arms). Primary endpoints: Safety (adverse events and GHDL values, Months 0-12) and Safety (adverse events and GHDL values, Months 12-36). Started Mar 2010; status: terminated.
02
Drugs
Sunphenon EGCG
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on 2009-016482-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016482-28.